Abbott's Q3 MDx Sales Rise 15 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Abbott today reported that its third quarter revenues increased 2 percent year over year, with a decline in pharmaceuticals sales offset by gains in its diagnostics business.

Overall, the firm reported sales of $5.37 billion, up from $5.27 million for the third quarter of 2012. Abbott's Nutrition and Medical Devices businesses both reported 2 percent revenue gains year over year, while Pharmaceuticals fell 3 percent. Its Diagnostics business, however, reported sales growth of 8 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.